Reuters - Video

Edition: U.S. | U.K. | IN | CN

Take 120

TAKE 120: Biotech Wars - Gilead Bests Biogen

Monday, December 17, 2012 - 02:40

Dec. 17 - Eaton Vance's Lew Piantedosi says Gilead has the potential to double its revenues based on its new Hepatitis C treatment and, trading at a discount to competitors, is the pick over Biogen.

▲ Hide Transcript

View Transcript

Press CTRL+C (Windows), CMD+C (Mac), or long-press the URL below on your mobile device to copy the code

TAKE 120: Biotech Wars - Gilead Bests Biogen

Monday, December 17, 2012 - 02:40